NON-ALCOHOLIC STEATOHEPATITIS (NASH) HAS BECOME THE MOST COMMON INDICATION FOR LIVER TRANSPLANTATION AMONG CANDIDATES WITH HEPATOCELLULAR CARCINOMA IN THE UNITED STATES
<div><p><b>Background:</p> </b><p>High prevalence of obesity in the U.S. is driving the burden of non-alcoholic steatohepatitis (NASH) and associated adverse clinical outcomes including NASH-related end-stage liver disease and hepatocellular carcinoma (HCC). Our aim was to assess the most recent trends in patients with chronic liver disease (CLD) listed for liver transplantation (LT) in the U.S. using a national registry.</p>